OSCA - Olaparib Standard of CAre Study (OSCA)
Real-World Treatment Patterns, BRCA Testing Practices, Outcomes, and Health Care Utilization in Platinum-Sensitive Recurrent Serous Ovarian Cancer: A Multi-Country Retrospective Study
Sponsor: A+A Healthcare Marketing Research
This observational or N/A phase trial investigates Platinum-sensitive Recurrent Serous Ovarian Cancer and is currently completed. A+A Healthcare Marketing Research leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- A+A Healthcare Marketing Research
- AstraZeneca
- Freelance CRA (FCRA)
- RTI Health Solutions
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarau, Switzerland , Afula, Israel , Aix-en-Provence, France , Ajaccio, France , Alberta, Canada , Alessandria, Italy , Alicante, Spain , Allschwil, Switzerland , Alzira, Valencia, Spain , Aosta, Italy and 189 more locations